Technical Analysis for IMCR - Immunocore Holdings plc

Grade Last Price % Change Price Change
D 51.12 0.89% 0.45
IMCR closed up 0.89 percent on Thursday, September 28, 2023, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Flat

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.89%
Multiple of Ten Bullish Other 0.89%
Down 3 Days in a Row Weakness 0.89%
Oversold Stochastic Weakness 0.89%
Multiple of Ten Bullish Other -0.04%
Oversold Stochastic Weakness -0.04%
Slingshot Bearish Bearish Swing Setup -1.77%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 13 hours ago
Down 2 % about 13 hours ago
10 DMA Resistance about 13 hours ago
Down 1% about 13 hours ago
Up 1% about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immunocore Holdings plc Description

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapy Autoimmune Disease Oncology Breast Cancer Immunotherapies Virotherapy Small Cell Lung Cancer Oncolytics Biotech Solid Tumor Cancers Treatment Of Autoimmune Disease Chronic Hepatitis B Virus Pelareorep Immunocore

Is IMCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 69.055
52 Week Low 44.795
Average Volume 212,396
200-Day Moving Average 57.55
50-Day Moving Average 58.43
20-Day Moving Average 53.48
10-Day Moving Average 51.25
Average True Range 2.08
RSI (14) 34.64
ADX 43.1
+DI 8.73
-DI 23.70
Chandelier Exit (Long, 3 ATRs) 51.76
Chandelier Exit (Short, 3 ATRs) 55.59
Upper Bollinger Bands 58.54
Lower Bollinger Band 48.42
Percent B (%b) 0.27
BandWidth 18.92
MACD Line -2.14
MACD Signal Line -2.15
MACD Histogram 0.0163
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.72
Resistance 3 (R3) 53.51 52.43 53.29
Resistance 2 (R2) 52.43 51.76 52.53 53.14
Resistance 1 (R1) 51.77 51.35 52.10 51.99 53.00
Pivot Point 50.69 50.69 50.86 50.80 50.69
Support 1 (S1) 50.04 50.03 50.37 50.25 49.24
Support 2 (S2) 48.96 49.62 49.06 49.10
Support 3 (S3) 48.30 48.96 48.95
Support 4 (S4) 48.52